Current ADA/EASD management guidelines in type 2 diabetes suggest that rosiglitazone should be avoided and states that the use of thiazolidinediones in general is less well-validated than the addition of a sulfonylurea or insulin to metformin when antidiabetic combination therapy is required (2). Here, INS is linked to type 2 diabetes mellitus.